GAITHERSBURG, Md., July 12, 2021 /PRNewswire/ -- MaxCyte, Inc.,
(LSE: MXCT) (LSE: MXCN), a leading provider of platform
technologies for cell engineering, today announced the public
filing of a registration statement on Form S-1 with the U.S.
Securities and Exchange Commission (the "SEC") relating to a
proposed dual listing of its shares of common stock on the Nasdaq
Global Market ("Nasdaq") under the symbol "MXCT." As
part of the proposed Nasdaq dual listing, MaxCyte is planning a
public offering of shares of its common stock in the United States (the
"Offering"). Upon completion of the Offering, MaxCyte's
common stock will continue to be admitted to trading on the AIM
market of the London Stock Exchange under the symbols "MXCT" and
"MXCN."
All shares to be sold in the Offering will be offered by
MaxCyte. The number of shares to be offered and the price range for
the proposed Offering have not yet been determined. The Offering is
expected to commence after the SEC completes its review process,
subject to market and other conditions. Stockholders and potential
investors should note that there is no guarantee as to whether or
when the potential Offering will proceed.
Cowen, Stifel and William Blair
are acting as joint book-running managers for the Offering and as
representatives of the underwriters for the proposed Offering. BTIG
and Stephens Inc. will also act as co-managers of the Offering.
The proposed Offering will be made only by means of a
prospectus. When available, copies of the preliminary prospectus
relating to and describing the terms of the Offering may be
obtained from the offices of Cowen and Company, LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus
Department, by telephone at (833) 297-2926 or by email at
PostSaleManualRequests@broadridge.com; Stifel, Nicolaus &
Company, Incorporated, Attention: Prospectus Department,
One Montgomery Street, Suite 3700,
San Francisco, CA 94104, by
telephone at +1 (415) 364-2720 or by email at
syndprospectus@stifel.com; or William
Blair & Company, L.L.C., Attention: Prospectus
Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at
1-800-621-0687 or by email at prospectus@williamblair.com.
A registration statement relating to these securities has been
filed with the SEC, but has not yet become effective. These
securities may not be sold, nor may offers to buy these securities
be accepted, prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities law of any
such state or jurisdiction.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. MaxCyte's existing
customer base ranges from large biopharmaceutical companies —
including all of the top 10, and 20 of the top 25, pharmaceutical
companies based on 2020 global revenue — to hundreds of
biotechnology companies and academic centers focused on
translational research. MaxCyte has granted 13 strategic platform
licenses to commercial cell therapy developers covering more than
75 programs under clinical licenses that are part of the strategic
platform licenses. MaxCyte was founded in 1998 and is headquartered
in Gaithersburg, Maryland, US.
MaxCyte Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Amanda Murphy, Chief Financial
Officer
+1-301-944-1660
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James
Black / Duncan Monteith /
Matthew O'Dowd
+44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams
+44 (0)20 7710 7600
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
US IR Adviser
Gilmartin Group
David Deuchler, CFA
david@gilmartinir.com
View original
content:https://www.prnewswire.com/news-releases/maxcyte-announces-public-filing-of-registration-statement-with-sec-for-a-proposed-nasdaq-dual-listing-301331150.html
SOURCE MaxCyte, Inc.